Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for DiaMedica Therapeutics, Inc. (DMAC : NSDQ)
 
 • Company Description   
DiaMedica Therapeutics Inc. is a biopharmaceutical company. It engages in the development of novel recombinant proteins and monoclonal antibodies. The companys lead product principally consists DM199, a recombinant human tissue kallikrein-1 protein. It operates primarily in the United States and Canada. DiaMedica Therapeutics Inc. is headquartered in Minneapolis, Minnesota.

Number of Employees: 15

 
 • Price / Volume Information   
Yesterday's Closing Price: $2.39 Daily Weekly Monthly
20 Day Moving Average: 57,035 shares
Shares Outstanding: 26.44 (millions)
Market Capitalization: $63.20 (millions)
Beta: 2.31
52 Week High: $9.55
52 Week Low: $2.12
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 10.14% 20.68%
12 Week -15.25% -8.04%
Year To Date -35.92% -23.80%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
2 CARLSON PARKWAY SUITE 260
-
MINNEAPOLIS,MN 55447
USA
ph: 763-312-6755
fax: 763-710-4456
ir@diamedica.com http://www.diamedica.com
 
 • General Corporate Information   
Officers
Rick Pauls - Chief Executive Officer; President and Director
Richard Pilnik - Chairman
Scott Kellen - Chief Financial Officer and Secretary
Amy L. Burroughs - Director
Michael Giuffre - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 25253X207
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/10/22
Share - Related Items
Shares Outstanding: 26.44
Most Recent Split Date: 11.00 (0.05:1)
Beta: 2.31
Market Capitalization: $63.20 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.16 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.68 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/10/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 1.55
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: 31.58%
vs. Previous Quarter: -30.00%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
03/31/22 - -35.43
12/31/21 - -40.42
09/30/21 - -49.94
ROA
03/31/22 - -34.08
12/31/21 - -38.74
09/30/21 - -47.35
Current Ratio
03/31/22 - 29.37
12/31/21 - 29.82
09/30/21 - 29.89
Quick Ratio
03/31/22 - 29.37
12/31/21 - 29.82
09/30/21 - 29.89
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Book Value
03/31/22 - 1.54
12/31/21 - 1.67
09/30/21 - 1.78
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 0.02
12/31/21 - 0.01
09/30/21 - 0.01
 

Powered by Zacks Investment Research ©